Genmab A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNMSF research report →
Companywww.genmab.com
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.
- CEO
- Jan van de Winkel
- IPO
- 2010
- Employees
- 2,638
- HQ
- Copenhagen, DK
Price Chart
Valuation
- Market Cap
- $16.55B
- P/E
- 6.29
- P/S
- 1.15
- P/B
- 2.90
- EV/EBITDA
- 4.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 93.88%
- Op Margin
- 39.61%
- Net Margin
- 18.23%
- ROE
- 20.51%
- ROIC
- 43.78%
Growth & Income
- Revenue
- $3.85B · -82.11%
- Net Income
- $996.93M · -87.29%
- EPS
- $16.04 · -86.88%
- Op Income
- $1.29B
- FCF YoY
- -84.32%
Performance & Tape
- 52W High
- $352.00
- 52W Low
- $198.51
- 50D MA
- $269.89
- 200D MA
- $290.95
- Beta
- 0.69
- Avg Volume
- 1.88K
Get TickerSpark's AI analysis on GNMSF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GNMSF Coverage
We haven't published any research on GNMSF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GNMSF Report →